Sharechat Logo

Truscreen Opto-electrical Technology Recognised

Wednesday 2nd August 2023

Text too small?

TruScreen opto-electrical technology recognized in China Cervical Cancer Screening Guideline by top national expert organisation



• China published the First national medical guideline in the world that recognises TruScreen technology

• China Cervical Cancer Screening Guideline (Guideline) of Chinese Society for Colposcopy and Cervical Pathology (CSCCP) recognises TruScreen technology in section “Other Cervical Cancer Screening Methods”

• The Guideline recognises TruScreen technology as the only AI enabled method for cervical cancer screening in China


Truscreen Group Limited (NZX/ASX:TRU) is pleased to advise that the CSCCP’s (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Guideline published in the July edition of CSCCP’s journal recognised TruScreen technology in the Chinese Journal of Clinical Gynaecology and Obstetrics in July 2023.


The formal publication follows from media announcement at major national congress of CSCCP in Beijing in May 2023.


CSCCP’s decision to include TruScreen technology in its new Guideline emphasises the role of new technology in the booming Chinese healthcare sector that focuses on AI and digitalisation of medical processes and practices. The decision is based on the body of evidence supporting TruScreen clinical use gathered in China and world-wide. The decision was also made after extensive consultations with healthcare practitioners and decision makers.


CSCCP is a member of IFCPC (The International Federation of Cervical Pathology and Colposcopy) which is dedicated to reducing the incidence of cervical cancer worldwide through the focus on basic and applied research, sharing of knowledge surrounding appropriate fields, and standardization of terminology in the field of cervical pathology. The guideline issued by CSCCP is a leading clinical standard for doctors and other healthcare clinicians and government agencies.


CEO, Dr Beata Edling commented:

“I am delighted to see TruScreen reaching this important technology acceptance milestone. The CSCCP recognition of TruScreen’s technology strengthens opportunities for transforming cervical cancer screening worldwide and will have a positive impact on our sales and marketing in the coming years.”

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

Devon Funds Morning Note - 21 June 2024
Infratil announces opening of NZ$150 million Retail Offer
NZGIF backs Sunergise with $10m lending facility
FBU Enters Agreement to Divest 50pc of Fiji Construction
FBU - WA Plumbing Australia - Response to BGC Claims
June 14th Morning Report
ENS - Enprise appoints Aaron Ridgway as a Non-Executive Director
AIR - Departure of Chief Corporate Affairs Officer